CD95 (FAS/APO-1) Antigen is a New Prognostic Marker of Blast Cells of Acute Lymphoblastic Leukaemia Patients

Авторы: Baryshnikov A.Yu, Polosukhina E.R., Tupitsin N.N., Gavrikova N.V., Andreeva L.Yu, Zabotina T.N., Mayakova S.A., Kurmashov V.I., Syrkin A.B., Kadagidze Z.G., Blochin D.Yu, Shishkin Yu V.
Сборник: Drug Resistance in Leukemia and Lymphoma III
Том: 457
Год издания: 1999
Место издания: Springer US Springer, Boston, MA
Первая страница: 251
Последняя страница: 258
DOI: 10.1007/978-1-4615-4811-9_27
Аннотация: We analyzed CD95(Fas/APO-l) antigen expression on bone marrow blasts in 38 children with acute lymphoblastic leukemia (ALL) receiving a treatment in the Department of Leukaemias at the Cancer Research Center in 1987–1989 years (n = 22) and in 1994–1997 years (n = 16). CD95 antigen expression was studied by monoclonal antibodies (MoAbs) IPO-4 in indirect immunofluorescence analysis. CD95 antigen was expressed on 35.8±7.5% bone marrow blasts, most frequently (63.6%) in the clinically favourable Pre-B ALL. Only in this group CD95 antigen expression was correlated with CD10 antigen expression that has a positive influence to the time of complete remission in ALL patients. Our data showed that CD95 expression on blast cells is a favourable prognostic sign, associated with increased relapse-free and total survival. On the contrary, the absence of CD95 antigen on blasts is an unfavourable sign for disease evolution.
Добавил в систему: Заботина Татьяна Николаевна

	ИСТИНА	Войти в систему Регистрация
	Интеллектуальная Система Тематического Исследования НАукометрических данных
	Главная Поиск Статистика О проекте Помощь

ИСТИНА